Annals of Surgical Oncology

, Volume 26, Issue 13, pp 4439–4444 | Cite as

Preoperative Computed Tomography Changes Surgical Management for Clinically Low-Risk Well-Differentiated Thyroid Cancer

  • Pim J. Bongers
  • Raoul Verzijl
  • Michael Dzingala
  • Menno R. Vriens
  • Eugene Yu
  • Jesse D. PasternakEmail author
  • Lorne E. Rotstein
Endocrine Tumors



In the current guidelines for differentiated thyroid cancer (DTC), computed tomography (CT) of the neck has a limited role. The authors hypothesized that adding CT to the workup of clinically low-risk DTC size 4 cm or smaller changes the surgical management for a portion of patients due to detection of clinically significant lymph node metastases not located by ultrasound of the neck.


A prospective cohort of DTC patients at an academic referral center between 2012 and 2016 was reviewed. All the patients with fine-needle aspiration cytopathology results suspicious for malignancy or malignant tumor (Bethesda category 5 or 6, respectively) underwent CT before surgery. Clinically low-risk DTC patients were selected if they had a tumor diameter of 4 cm or less and no evidence for local invasion or suspicious lymph nodes seen on ultrasound. Outcomes focused on alteration of the surgical plan based on CT and correlation with pathology.


The CT findings for 25 (22.5%) of 111 patients with clinically low-risk DTC led to a change in surgical management. Of these 25 patients, 16 (14.4% of the entire cohort) benefited due to the removal of clinically significant lymph node disease not seen on ultrasound. Categorization of the group that had a change in management showed that 6 (85.7%) of 7 lateral neck dissections and 10 (55.6%) of 18 central neck dissections (CND) harbored metastatic nodes larger than 2 mm.


In the group with clinically low-risk DTC, CT changed surgical management for a substantial number of the patients with clinically significant nodal disease not detected by ultrasound. This highlights the fact that in certain practice settings, adding CT to the preoperative staging may be favorable for the detection of nodal metastasis.



The authors declare that they have no conflict of interest.


  1. 1.
    Davies L, Morris LG, Haymart M, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Disease state clinical review: the increasing incidence of thyroid cancer. Endocrine Practice. 2015;21:686–96.CrossRefGoogle Scholar
  2. 2.
    Davies L, Welch H. Thyroid cancer survival in the United States: observational data from 1973 to 2005. Arch Otolaryngol Head Neck Surg. 2010;136:440–4.CrossRefGoogle Scholar
  3. 3.
    Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. 2017;317:1338–48.CrossRefGoogle Scholar
  4. 4.
    Nixon IJ, Wang LY, Migliacci JC, et al. An international multi-institutional validation of age 55 years as a cutoff for risk stratification in the AJCC/UICC staging system for well-differentiated thyroid cancer. Thyroid. 2016;26:373–80.CrossRefGoogle Scholar
  5. 5.
    Choi JS, Kim J, Kwak JY, Kim MJ, Chang HS, Kim E-KK. Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT. AJR Am J Roentgenol. 2009;193:871–8.Google Scholar
  6. 6.
    Lee DY, Kwon T-KK, Sung M-WW, Kim KH, Hah JH. Prediction of extrathyroidal extension using ultrasonography and computed tomography. Int J Endocrinol. 2014. Scholar
  7. 7.
    Choi J, Chung W, Kwak J, Moon H, Kim M, Kim E-K. Staging of papillary thyroid carcinoma with ultrasonography: performance in a large series. Ann Surg Oncol. 2011;18:3572–8.CrossRefGoogle Scholar
  8. 8.
    Gonzalez HE, Cruz F, O’Brien A, et al. Impact of preoperative ultrasonographic staging of the neck in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2007;133:1258–62.CrossRefGoogle Scholar
  9. 9.
    Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery. 2003;134:946.CrossRefGoogle Scholar
  10. 10.
    Stulak JM, Grant CS, Farley DR, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg. 2006;141:486–9.CrossRefGoogle Scholar
  11. 11.
    Ahn J, Lee J, Yi J, et al. Diagnostic accuracy of CT and ultrasonography for evaluating metastatic cervical lymph nodes in patients with thyroid cancer. World J Surg. 2008;32:1552.CrossRefGoogle Scholar
  12. 12.
    Kim E PJ, Son K-R, Kim J-H, Jeon SJ, Na DG. Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: comparison of ultrasound, computed tomography, and combined ultrasound with computed tomography. Thyroid. 2008;18:411–8.CrossRefGoogle Scholar
  13. 13.
    Lee DW, Ji YB, Sung ES, et al. Roles of ultrasonography and computed tomography in the surgical management of cervical lymph node metastases in papillary thyroid carcinoma. Eur J Surg Oncol. 2013;39:191–6.CrossRefGoogle Scholar
  14. 14.
    Lesnik D, Cunnane ME, Zurakowski D, et al. Papillary thyroid carcinoma nodal surgery directed by a preoperative radiographic map utilizing CT scan and ultrasound in all primary and reoperative patients. Head Neck. 2014;36:191–202.CrossRefGoogle Scholar
  15. 15.
    Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients With thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.CrossRefGoogle Scholar
  16. 16.
    Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol. 2009;132:658–65.CrossRefGoogle Scholar
  17. 17.
    Kim SK, Woo J-WW, Park I, et al. Computed tomography-detected central lymph node metastasis in ultrasonography node-negative papillary thyroid carcinoma: is it really significant? Ann Surg Oncol. 2017;24:442–9.Google Scholar
  18. 18.
    Hartl DM, Leboulleux S, Vélayoudom-Céphise F-LL, Mirghani H, Déandréis D, Schlumberger M. Management of retropharyngeal node metastases from thyroid carcinoma. World J Surg. 2015;39:1274–81.Google Scholar
  19. 19.
    Togashi T, Sugitani I, Toda K, Kawabata K, Takahashi S. Surgical management of retropharyngeal nodes metastases from papillary thyroid carcinoma. World J Surg. 2014;38:2831–7.CrossRefGoogle Scholar
  20. 20.
    Adam MA, Thomas S, Youngwirth L, et al. Is there a minimum number of thyroidectomies a surgeon should perform to optimize patient outcomes? Ann Surg. 2017;265:402–7.CrossRefGoogle Scholar
  21. 21.
    Oltmann SC, Schneider DF, Chen H, Sippel RS. All thyroid ultrasound evaluations are not equal: sonographers specialized in thyroid cancer correctly label clinical N0 disease in well-differentiated thyroid cancer. Ann Surg Oncol. 2015;22:422–8.CrossRefGoogle Scholar
  22. 22.
    Rosario PW. Ultrasonography for the follow-up of patients with papillary thyroid carcinoma: how important is the operator? Thyroid. 2010;20:833–4.CrossRefGoogle Scholar
  23. 23.
    Smith-Bindman R, Lipson J, Marcus R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med. 2009;169:2078–86.CrossRefGoogle Scholar
  24. 24.
    Mishra A, Pradhan P, Gambhir S, Sabaretnam M, Gupta A, Babu S. Preoperative contrast-enhanced computerized tomography should not delay radioiodine ablation in differentiated thyroid carcinoma patients. J Surg Res. 2015;193:731–7.CrossRefGoogle Scholar
  25. 25.
    Padovani RP, Kasamatsu TS, Nakabashi CCD, et al. One month is sufficient for urinary iodine to return to its baseline value after the use of water-soluble iodinated contrast agents in post-thyroidectomy patients requiring radioiodine therapy. Thyroid. 2012;22:926–30.CrossRefGoogle Scholar
  26. 26.
    Sohn S, Choi J, Kim N, et al. The impact of iodinated contrast agent administered during preoperative computed tomography scan on body iodine pool in patients with differentiated thyroid cancer preparing for radioactive iodine treatment. Thyroid. 2014;24:872–7.CrossRefGoogle Scholar
  27. 27.
    Hong Y, Lee S, Lim D, et al. The stratification of patient risk depending on the size and ratio of metastatic lymph nodes in papillary thyroid carcinoma. World J Surg Oncol. 2017;15:74.CrossRefGoogle Scholar
  28. 28.
    Lang B, Tang AH, Wong K, Shek TW, Wan K, Lo C-Y. Significance of size of lymph node metastasis on postsurgical stimulated thyroglobulin levels after prophylactic unilateral central neck dissection in papillary thyroid carcinoma. Ann Surg Oncol. 2012;19:3472–8.CrossRefGoogle Scholar
  29. 29.
    Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg. 2009;34:28–35.CrossRefGoogle Scholar
  30. 30.
    Wada N, Masudo K, Nakayama H, et al. Clinical outcomes in older or younger patients with papillary thyroid carcinoma: impact of lymphadenopathy and patient age. Eur J Surg Oncol. 2008;34:202–7.CrossRefGoogle Scholar
  31. 31.
    Bardet S, Malville E, Rame J-P, et al. Macroscopic lymph node involvement and neck dissection predict lymph node recurrence in papillary thyroid carcinoma. Eur J Endocrinol. 2008;158:551–60.CrossRefGoogle Scholar
  32. 32.
    Randolph GW, Duh Q-YY, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012;22:1144–52.Google Scholar
  33. 33.
    Vaisman F, Tala H, Grewal R, Tuttle MR. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. Thyroid. 2011;21:1317–22.CrossRefGoogle Scholar
  34. 34.
    Wang LY, Roman BR, Migliacci JC, et al. Cost-effectiveness analysis of papillary thyroid cancer surveillance. Cancer. 2015;121:4132–40.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Pim J. Bongers
    • 1
    • 2
  • Raoul Verzijl
    • 1
    • 2
  • Michael Dzingala
    • 1
  • Menno R. Vriens
    • 2
  • Eugene Yu
    • 3
  • Jesse D. Pasternak
    • 1
    Email author
  • Lorne E. Rotstein
    • 1
  1. 1.Department of SurgeryUniversity Health NetworkTorontoCanada
  2. 2.Department of Surgical Oncology and Endocrine SurgeryUniversity Medical Center UtrechtUtrechtThe Netherlands
  3. 3.Department of Medical ImagingUniversity Health NetworkTorontoCanada

Personalised recommendations